Overview
- The FDA cleared a once‑weekly 500 mg subcutaneous starter dose of Leqembi Iqlik on Monday, July 13, permitting some patients to begin treatment with self‑ or caregiver‑administered injections at home.
- Regulators based the approval on bridging and exposure‑response data showing subcutaneous drug exposure equivalent to the approved 10 mg/kg biweekly IV regimen rather than on new large clinical outcome trials.
- The approved initiation regimen is 500 mg given weekly as two 250 mg autoinjector injections that each take about 15 seconds, and maintenance dosing may transition to 360 mg once weekly after roughly 18 months.
- Clarity AD substudies and related analyses reported comparable amyloid plaque reduction and similar ARIA risk estimates between subcutaneous and IV dosing, with fewer systemic infusion reactions and mostly mild local injection reactions reported in small cohorts.
- Advocates and analysts say at‑home initiation could widen access, lower caregiver and clinic burden and help enable longer or combination Alzheimer’s regimens, but clinicians will still need robust monitoring for ARIA and stronger diagnostic and care infrastructure.